Gapping upIn reaction to strong earnings/guidance:
- HTZ +16.2%, REV +10.1%, ERI +8.6%, DBX +8.5%, CDNA +6.7%, MGI +5.6%, UPLD +5.5%, SUP +5.4%, LGF.A +5.3%, AL +5%, RDNT +4.9%, UMC +4.7% (Oct sales) SPPI +4.4%, FSCT +4.2%, OSTK +4%, MIME +4%, WSC +3%, FOE +2.8%, JAG +2.8%, SCOR +2.8%, SSP +2.8%, ALTR +2.6%, SENS +2.5%, SYNA +2.3%, HDP +1.8%, DIS +1.7%, AGS +1.6%, SSRM +1.5%, AMPH +1.4%, CBPX +1.1%
M&A news:
- FNSR +22.4% (to be acquired by II-VI (IIVI) in cash and stock transaction, valued at $26.00 per share)
Other news:
- ZIOP +10.9% (rescheduled its quarterly conference call to Monday, Nov. 12 - will file 10-Q tomorrow)
- STNE +4.5% (Warren Buffet's Berkshire Hathaway (BRK.A/B) discloses a 11.3% passive stake)
- CAR +3.8% (following HTZ results)
- CRSP +0.8% (CRISPR Therapeutics and MaxCyte enter nto a non-exclusive commercial license agreement that will allow CRISPR Therapeutics to deploy MaxCyte's Flow Electroporation Technology to develop CRISPR/Cas9-based therapies in immuno-oncology)
Analyst comments:
- CREE +3.4% (upgraded to Buy from Neutral at Goldman)
- KPTI +2.6% (upgraded to Outperform from Neutral at Wedbush)
- CADE +1.6% (upgraded to Outperform from Mkt Perform at Keefe Bruyette)
- NDLS +1.4% (upgraded to Neutra from Underweightl at Piper Jaffray)
- AAXN +1% (upgraded to Outperform from Neutral at Robert W. Baird)